Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Search Results

Your search returned 1870 record(s).

Page 137 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:

  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
1361 8.9 months Advanced NSCLC 4 Biologic therapy
University College Hospital United Kingdom 11/2009
Treatment Details: Patients: This phase 3 study involved 722 patients with stage IIIb or IV (advanced) non-small cell lung cancer. They ranged in age from 33 to 84 years of age. The majority (about 65%) were
1362 8.9 months Advanced hepatocellular carcinoma 4 Biologic therapy
Istituto Clinico Humanitas Italy 9/2010
Treatment Details: Patients: This study involved 27 patients with advanced hepatocellular carcinoma. The median age of the group was 67 years and 82% were male. Treatment: Patients in this study were adm
1363 8.8 months Metastatic renal cell carcinoma 4 Biologic therapy
Memorial Sloan-Kettering Cancer Center United States 8/2008
Treatment Details: Patients: This phase III study 410 patients with metastatic renal cell carcinoma (kidney cancer). They ranged in age from 27 to 85 years. The majority (77%) of these patients were men.
1364 8.8 months MPM 4 Chemotherapy
St. Bartholomew's Hospital United Kingdom 2/2005
Treatment Details: Patients: This Phase II study involved 26 patients with malignant pleural mesothelioma. Twenty-one patients were men, and five were women. The median age was 60 years. None of the patient
1365 8.8 months Advanced NSCLC 4 Chemotherapy
University General Hospital of Heraklion Greece 10/2005
Treatment Details: Patients: This Phase II study involved 139 patients with advanced non-small-cell lung cancer. All patients were treated previously with taxanes and gemcitabine. The patients were randomize
1366 8.8 months Malignant Pleural Mesothelioma 4 Chemotherapy
University Hospital Vrije Universiteit Netherlands 11/1997
Treatment Details: Patients: This Phase II trial involved 41 patients with malignant pleural mesothelioma. Treatment: The treatment consisted of a chemotherapy drug, oral etoposide (VP 16-213, vepesid).
1367 8.8 months Inoperable advanced NSCLC 4 Chemotherapy
Helen F. Graham Cancer Center United States 9/2002
Treatment Details: Patients: This Phase I study involved 30 patients with inoperable advanced (stage IIIB or IV) non-small cell lung cancer. No patients had been administered prior chemotherapy. Treatment:
1368 8.8 months Recurrent grade IV gliomas 3 Biologic therapy
University of California, San Francisco, School of Medicine United States 12/2002
Treatment Details: Patients: This Phase II study involved 26 patients with recurrent malignant gliomas. Fourteen had glioblastoma multiforme or gliosarcoma (i.e. grade IV), and there were 12 patients with gra
1369 8.8 months Recurrent or progressive malignant gliomas 4 Chemotherapy
M.D. Anderson Cancer Center, University of Texas United States 1/2002
Treatment Details: Patients: This Phase I/II study involved 24 patients with recurrent or progressive malignant gliomas. Sixteen patients had glioblastoma multiforme, six patients had anaplastic astrocytoma,
1370 8.8 months Metastatic colorectal carcinoma 5 Chemotherapy
Antwerp University Hospital Belgium 2/2013
Treatment Details: Patients: This phase 2 study involved previously treated metastatic colorectal cancer patients who were separated into two treatment groups. Group A consisted of 95 patients with a median
Page 137 of 187  | Previous Page  | Next Page